Posted by Michael Wonder on 29 Aug 2020
FDA broadens emergency use authorisation for Veklury (remdesivir) to include all hospitalised patients for treatment of COVID-19
28 August 2020 - Today, as part of its ongoing efforts to fight COVID-19, the U.S. FDA broadened the scope of the existing emergency use authorisation for the drug Veklury (remdesivir) to include treatment of all hospitalised adult and paediatric patients with suspected or laboratory-confirmed COVID-19, irrespective of their severity of disease.
In May 2020, the FDA issued an emergency use authorisation that authorised Veklury for the treatment of hospitalised adult and paediatric patients with severe COVID-19.
As noted in the initial issuance of the EUA, the emergency use of Veklury was limited to those patients with severe disease, which was defined as patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator.
